Financial reports
10-K
2023 FY
Annual report
19 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
8 May 23
10-K/A
2022 FY
Annual report (amended)
27 Apr 23
10-K
2022 FY
Annual report
28 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
Current reports
8-K
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
19 Mar 24
8-K
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
10 Jan 24
8-K
Departure of Directors or Certain Officers
20 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
15 Nov 23
8-K
Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
14 Nov 23
8-K
Departure of Directors or Certain Officers
1 Nov 23
8-K
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
26 Sep 23
8-K
Taysha will pursue external strategic options for the TSHA-120 program to potentially enable further program development
19 Sep 23
8-K
Other Events
29 Aug 23
8-K
Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
24 Aug 23
Registration and prospectus
S-8
Registration of securities for employees
19 Mar 24
S-8
Registration of securities for employees
20 Dec 23
424B3
Prospectus supplement
11 Sep 23
S-3
Shelf registration
30 Aug 23
D
$150.00 mm in equity / options, sold $149.95 mm, 42 investors
25 Aug 23
424B3
Prospectus supplement
4 May 23
S-3
Shelf registration
5 Apr 23
424B5
Prospectus supplement for primary offering
28 Mar 23
S-8
Registration of securities for employees
28 Mar 23
D
$30.00 mm in equity, sold $30.00 mm, 1 investor
7 Nov 22
Proxies
DEF 14A
Definitive proxy
5 Oct 23
PRE 14A
Preliminary proxy
21 Sep 23
DEFA14A
Additional proxy soliciting materials
8 May 23
DEF 14A
Definitive proxy
8 May 23
PRE 14A
Preliminary proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
DEF 14A
Definitive proxy
29 Apr 21
Other
EFFECT
Notice of effectiveness
11 Sep 23
CORRESP
Correspondence with SEC
7 Sep 23
UPLOAD
Letter from SEC
6 Sep 23
EFFECT
Notice of effectiveness
2 May 23
CORRESP
Correspondence with SEC
27 Apr 23
UPLOAD
Letter from SEC
7 Apr 23
EFFECT
Notice of effectiveness
15 Oct 21
CORRESP
Correspondence with SEC
12 Oct 21
UPLOAD
Letter from SEC
12 Oct 21
EFFECT
Notice of effectiveness
24 Sep 20
Ownership
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
TCG Crossover GP I, LLC
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Kamran Alam
6 Feb 24
4
Kamran Alam
4 Jan 24
4
Sukumar Nagendran
4 Jan 24
4
Sean P. Nolan
4 Jan 24
4
Kamran Alam
18 Dec 23